<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700488</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000573</org_study_id>
    <nct_id>NCT04700488</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)</brief_title>
  <official_title>MRI Imaging to Predict Outcomes of Treatment in PDAC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI)&#xD;
      is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic&#xD;
      Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e.&#xD;
      vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression-free survival from baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival will be determined by tumor activity assessed from radiomic features on imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with R0 resection</measure>
    <time_frame>2 years</time_frame>
    <description>The rate of negative tumor resection margins for patient's with resectable cancer that undergo surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in overall health from baseline, as measured by the Charlson Comorbidity Index (CCI)</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Scores are summed depending on the patient's age and the presence of certain comorbidities. Lower scores are correlated to higher overall survival rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in functional status from baseline, as measured by the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Scores range from 0 to 4, with 0 denoting fully active and 1-4 for varying degrees of disability.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>PDAC - Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>6D-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6D-MRI</intervention_name>
    <description>Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI</description>
    <arm_group_label>6D-MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pancreatic cancer patients (with resectable or borderline resectable or locally&#xD;
             advanced tumors) who will undergo neoadjuvant chemotherapy&#xD;
&#xD;
          -  Patients able to undergo at least two sets of MRI sessions&#xD;
&#xD;
          -  Access to a device that has the capability to sync to the Fitbit (or access to a&#xD;
             family member's, caregiver's, or friend's device)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously been treated for PDAC&#xD;
&#xD;
          -  Patients unable to undergo MRI exam w/contrast&#xD;
&#xD;
          -  Patients with metastatic pancreatic cancer visualized on index diagnostic imaging&#xD;
&#xD;
          -  Patients with certain metallic implants&#xD;
&#xD;
          -  Patients experiencing claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Pandol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Meza</last_name>
    <phone>310-423-6082</phone>
    <email>Joseph.Meza@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Meza</last_name>
      <phone>310-423-6082</phone>
      <email>joseph.meza@cshs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Stephen Pandol</investigator_full_name>
    <investigator_title>Director of Basic and Translational Pancreas Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

